Found: 18
Select item for more details and to access through your institution.
Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma.
- Published in:
- Genes, Chromosomes & Cancer, 2009, v. 48, n. 1, p. 10, doi. 10.1002/gcc.20615
- By:
- Publication type:
- Article
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-38891-x
- By:
- Publication type:
- Article
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
- Published in:
- Genome Medicine, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13073-021-00990-z
- By:
- Publication type:
- Article
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.
- Published in:
- Nature, 2011, v. 480, n. 7375, p. 99, doi. 10.1038/nature10630
- By:
- Publication type:
- Article
Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00478-6
- By:
- Publication type:
- Article
Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy.
- Published in:
- Genome Medicine, 2024, v. 16, n. 1, p. 1, doi. 10.1186/s13073-024-01362-z
- By:
- Publication type:
- Article
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
- Published in:
- Nature Genetics, 2012, v. 44, n. 2, p. 165, doi. 10.1038/ng.1041
- By:
- Publication type:
- Article
Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 2, p. 1, doi. 10.1093/jnci/dju408
- By:
- Publication type:
- Article
Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
- Published in:
- Molecular Oncology, 2019, v. 13, n. 7, p. 1503, doi. 10.1002/1878-0261.12497
- By:
- Publication type:
- Article
Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer.
- Published in:
- Molecular Oncology, 2019, v. 13, n. 4, p. 738, doi. 10.1002/1878-0261.12422
- By:
- Publication type:
- Article
Cross-Platform Array Screening Identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as Genes Frequently Silenced by Methylation in Melanoma.
- Published in:
- PLoS ONE, 2011, v. 6, n. 10, p. 1, doi. 10.1371/journal.pone.0026121
- By:
- Publication type:
- Article
Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.
- Published in:
- Pigment Cell & Melanoma Research, 2011, v. 24, n. 3, p. 525, doi. 10.1111/j.1755-148X.2011.00849.x
- By:
- Publication type:
- Article
H-Cadherin expression reduces invasion of malignant melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2009, v. 22, n. 3, p. 296, doi. 10.1111/j.1755-148X.2009.00568.x
- By:
- Publication type:
- Article
Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples.
- Published in:
- BMC Medical Genomics, 2019, v. 12, n. 1, p. 1, doi. 10.1186/s12920-019-0476-9
- By:
- Publication type:
- Article
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-74956-3
- By:
- Publication type:
- Article
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1220129
- By:
- Publication type:
- Article
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy -- results from the AGITG DOCTOR trial and the cancer evolution biobank.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1220129
- By:
- Publication type:
- Article